Anecdotal studies of antitumour necrosis factor agents
| Disease | Author(s) | Drugs | Patients (n) |
| Adult Still’s disease | Huffstutter et al501 | Infliximab | 2 |
| Kraetsch et al502 | Infliximab | 6 | |
| Weinblatt et al503 | Etanercept | 12 | |
| Fernandez-Nebro504 | Etanercept | 3 | |
| Amyloidosis | Elkayam et al505 | Infliximab | 1 |
| Gottenberg et al506 | Etanercept/infliximab | 15 | |
| Ortiz-Santamaria et al507 | Infliximab | 6 | |
| Tomero et al508 | Infliximab | 12 | |
| Smith et al509 | Etanercept | 1 | |
| Aphthous stomatitis | Robinson and Guitart510 | Etanercept | 1 |
| Vujevich and Zirwas511 | Adalimumab | ||
| Atzeni et al512 | Etanercept | 1 | |
| Back pain (including sciatica) | Sakellariou et al513 | lnfliximab | 1 |
| Genevay et al514 | Etanercept | 10 | |
| Behçet’s disease | Estrach et al515 | Infliximab/adalimumab | 7 |
| Gulli et al516 | Infliximab | 1 | |
| Hassard et al517 | Infliximab | 1 | |
| Licata et al518 | Infliximab | 1 | |
| Magliocco and Gottlieb519 | Etanercept | 20 | |
| Morillas-Arques et al520 | Adalimumab/etanercept | ||
| Rozenbaum et al521 | Anti-TNF | ||
| Saulsbury and Mann522 | Infliximab | ||
| Sangle et al523 | Infliximab | 1 | |
| Sfikakis et al524 | Infliximab | 5 | |
| Sfikakis525 | Infliximab | 11 | |
| Ribi et al526 | Infliximab | 1 | |
| Sweiss et al527 | Infliximab | 3 | |
| van Laar et al528 | Adalimumab | 6 | |
| Bronchiolitis | Cortot et al529 | Etanercept | 1 |
| Cirrhosis and alcoholic hepatitis | Naveau et al530 | Infliximab | 36 |
| Spahr et al531 | Infliximab | 20 | |
| Wendling et al282 | Infliximab | 1 | |
| Menon et al532 | Etanercept | 13 | |
| Congestive heart failure | Anker et al582 | Infliximab/etanercept | 150 |
| Cutaneous T-cell lymphoma | Tsimberidou et al533 | Etanercept | 13 |
| Dermatitis, hidradenitis, miscellaneous | Bongartz et al339 | Infliximab | |
| Cortis et al534 | Etanercept | ||
| Cummins et al535 | Etanercept | ||
| Zeichner et al536 | Adalimumab | 1 | |
| Cusak and Buckley537 | Etanercept | 6 | |
| Dermatomyositis | Hengstman et al538 | Infliximab | 2 |
| Miller et al539 | Etanercept | 10 | |
| Sprott et al540 | Etanercept | 1 | |
| Nzeusseu et al541 | Infliximab | 1 | |
| Saadeyh542 | Etanercept | 4 | |
| Norman et al543 | Etanercept | 2 | |
| Erythema nodosum | Ortego-Centeno et al120 | Adalimumab | 1 |
| Familial Mediterranean fever | Takada et al122 | Etanercept | 2 |
| Ozgocmen et al125 | Etanercept | 1 | |
| Felty’s syndrome | Ghavami et al128 | Etanercept | 1 |
| Giant cell arteritis | Andonopoulos et al126 | Infliximab | 2 |
| Cantini et al127 | Infliximab | 4 | |
| Tan et al135 | Etanercept | 1 | |
| Ahmed et al133 | Adalimumab | 1 | |
| Graft vs host disease (acute) | Wolff et al544 | Etanercept | 21 |
| Uberti et al545 | Etanercept | 20 | |
| Kennedy et al546 | Etanercept | 20 | |
| Chiang et al547 | Etanercept | 8 | |
| Pavletic et al548 | Etanercept | 4 | |
| Andolina et al549 | Etanercept | 1 | |
| Graves ophthalmopathy | Paridaens et al550 | Etanercept | 10 |
| Hepatitis C | Cacoub et al551 | Interferon | 27 |
| McMinn et al552 | Etanercept | 3 | |
| Peterson et al553 | Infliximab/etanercept | 24 | |
| Pritchard554 | Etanercept | 1 | |
| Ince et al555 | Etanercept | 12 | |
| Moreno et al556 | Etanercept | 5 | |
| Allen and Wolverton470 | Etanercept | 2 | |
| Marotte et al557 | Etanercept | 9 | |
| Rokhsar et al558 | Etanercept | 1 | |
| Magliocco and Gottlieb519 | Etanercept | 3 | |
| HIV | Wallis et al559 | Etanercept | 16 |
| Immunodeficiency (common variable) | Smith and Skelton560 | Etanercept | 1 |
| Lin et al561 | Etanercept | 1 | |
| Cepeda et al562 | Etanercept | 7 | |
| Inclusion body myositis | Barohn et al563 | Etanercept | 9 (ineffective) |
| Singh et al564 | Etanercept | 1 | |
| Juvenile-onset HLA-B27- associated severe and refractory heal enthesitis | Olivieri et al565 | Adalimumab | 1 |
| Kawasaki’s disease | Weiss et al566 | Infliximab | 1 |
| Burns et al567 | Infliximab | 16 | |
| Multicentric histiocytosis | Lovelace et al108 | Etanercept | 1 |
| Matejicka et al143 | Etanercept | 1 | |
| Kovach et al568 | Etanercept | 1 | |
| Myelodysplasia | Birnbaum and Gentile569 | Etanercept | 1 |
| Deeg et al570 | Etanercept | 14 | |
| Rosenfeld and Bedell571 | Etanercept | 19 (ineffective) | |
| Raza et al572 | Etanercept | 26 | |
| Maciejewski573 | Etanercept | 16 | |
| Osteoarthritis (erosive) | Magnano et al574 | Adalimumab | 12 |
| Periodic fever (children) | Athreya et al575 | Etanercept | 3 |
| Pigmented villonodular synovitis | Kroot et al576 | TNF | |
| Polychondritis | Carter578 | Infliximab | 1 |
| Ehresman579 | Etanercept | 5 | |
| Polymyositis | Hengstman et al538 | Infliximab | 2 |
| Sprott et al540 | Etanercept | 1 | |
| Adams et al577 | Adalimumab | 2 | |
| Pyoderma gangrenosum | Fonder et al580 | Adalimumab | 1 |
| Heffernan et al581 | Adalimumab | 1 | |
| SAPHO syndrome | Wagner et al131 | Etanercept | 2 |
| Moul and Korman132 | Adalimumab | 1 | |
| Sarcoidosis | Khanna et al129 | Etanercept | 1 |
| Utz et al130 | Etanercept | 17 | |
| Heffernan et al134 | Adalimumab | 1 | |
| Callejas-Rubio et al584 | Adalimumab | 1 | |
| Thumbfart317 | Infliximab | 1 | |
| Sweiss et al583 | Infliximab | 3 | |
| Hobbs586 | Etanercept | 1 | |
| Soiatica | Korhonen et al118 | Infliximab | 12 |
| Korhonen et al119 | Infliximab | 40 | |
| Tobinick and Davoodifar124 | Etanercept | 43 | |
| Scleroderma | Ellman et al587 | Etanercept | 8 |
| Bosello et al588 | Etanercept | ||
| Lam et al121 | Infliximab | 18 | |
| Silicone granulomas | Pasternack et al123 | Etanercept | 4 |
| Sjögren’s syndrome | Zandbelt et al589 | Etanercept | 15 (ineffective) |
| Sankar et al212 | Etanercept | 14 (ineffective) | |
| Pessler et al590 | Etanercept | 1 | |
| Still’s disease (includes adult onset) | Fautrel et al591 | Etanercept | 20 (ineffective) |
| Stern et al592 | Etanercept | 1 (worsening) | |
| Asherson et al593 | Etanercept | 1 | |
| Kumari and Uppal594 | Etanercept | 1 | |
| Sweet’s syndrome | Gindi et al595 | Etanercept | 1 |
| Yamauchi et al596 | Etanercept | 24 | |
| Systemic lupus erythematosus | Aringer et al597 | Infliximab | 6 |
| Fautrel et al591 | Etanercept | 1 (SCLE) | |
| Lurati et al598 | Etanercept | 1 | |
| Norman et al543 | Etanercept | 1 (SCLE) | |
| Hernandez-Ibarra et al599 | N/A | – | |
| Principi et al600 | Infliximab | 1 | |
| Takayasu’s arteritis | Hoffman et al601 | Anti-TNF | 15 |
| Della Rossa et al602 | Infliximab | 2 | |
| Tato et al603 | Adalimumab | 1 | |
| TRAPS | Hull et al604 | Etanercept | >50 |
| Lamprecht et al605 | Etanercept | 2 | |
| Drewe et al606 | Etanercept | 1 | |
| Estrach et al607 | Infliximab/adalimumab | 7 | |
| Joseph et al607 | Infliximab | 5 | |
| Smith et al608 | Etanercept | 7 | |
| Braun et al609 | Etanercept/infliximab | 717 (uveitis in AS) | |
| Foster et al610 | Etanercept | 20 (ineffective) | |
| Biester et al611 | Adalimumab | 18 | |
| Foeldvari et al612 | Anti-TNFα | 47 | |
| Vazquez-Cobian et al613 | Adalimumab | 14 | |
| Reiff et al614 | Etanercept | 10 | |
| Schmeling and Horneff615 | Etanercept | 20 (ineffective) | |
| Vasculitis* | Booth et al616 | Infliximab | 32 |
| Feinstein and Arroyo617 | Etanercept | 1 | |
| van der Bijl et al618 | Infliximab | 11 | |
| Saji and Kemmotsu619 | Infliximab | 1 (Kawasaki’s disease) | |
| Sangle et al523 | Infliximab | 1 (Churg–Strauss) | |
| Arbach et al620 | Etanercept/infliximab | 3 | |
| Wegener’s granulomatosis | Gause et al621 | Infliximab | 10 |
| Sangle et al523 | Infliximab | 3 |
*See also Behçet’s disease, giant cell arteritis,Takayasu’s arteritis, Wegener’s
granulomatosis.
AS, ankylosing spondylitis; SCLE, subacute cutaneous lupus erythematosus.